Loading
A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting.
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b is a phase 1/2 interventional study registered as NCT03319628 by Mersana Therapeutics, with 523 participants enrolled, started 2017-12-12 and due to reach its primary completion in 2023-05-31. Interventions recorded: upifitamab rilsodotin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/